Wire · opportunities
Teva autoimmune antibody notches ph. 2 win in celiac disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
Teva Pharmaceuticals announced positive phase 2a trial results for its anti-IL-15 antibody TEV ‘408 in celiac disease, demonstrating significant reduction in gluten-induced intestinal damage with no safety concerns. The drug targets IL-15, a proinflammatory protein with no current approved inhibitors, and is also being tested in vitiligo with plans for further clinical development.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 2 Sep 2026 and 3 Sep 2026.
◆ ◆ The Wire takeaway
Your autoimmune drug development just cleared a key clinical milestone validating IL-15 as a target; prioritise engagement with celiac and vitiligo clinicians to build early clinical partnerships and accelerate regulatory paths.
◆ Coverage
3 sources · first reported 2 Sep 2026 · latest 3 Sep 2026
◆ Related on Wire
◆ Topics